JNJ241227C126000
- 17.97
- 0.000.00%
Johnson & Johnson Newsroom
Why the 'Dogs of the Dow' Stocks Just Might Deliver in 2025
RxSight Cut to Hold at Stifel on Competition Concerns
After GE's Spinoff Success, What's Next for Honeywell, FedEx
Your Healthcare Costs Are Soaring! US Spending Reached $5 Trillion In 2023 With Major Increase in Obesity and Diabetes Drugs, Hospital Services
Why Is Johnson & Johnson (JNJ) Among the Best Dividend Stocks to Invest In?
Dow's Drop: How Blue-chips Have Fared During Index's Peak Turned Worst-run in Decades
Least Shorted S&P 500 Stocks in November
Dow on a Record Losing Streak: Should You Buy Its ETF?
Express News | J&J: Application to EMA for New Indication Approval for Imbruvica in Adults With Previously Untreated Mcl Eligible for Autologous Stem Cell Transplant
Express News | U.S. FDA Approves Celltrion's Steqeyma, Biosimilar to J&J's Stelara - Website
Express News | Brokerages are pursuing large model empowerment for investment research, and Analysts are making further progress in writing Research Reports using AI.
FDA Rejects Johnson & Johnson's Injectable Version Of Approved Drug For Lung Cancer
Bernstein Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $161
Morgan Stanley Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $175
FDA Gives CRL to J&J's BLA for Subcutaneous Rybrevant in NSCLC
Johnson & Johnson (NYSE:JNJ) Has A Pretty Healthy Balance Sheet
Johnson & Johnson (JNJ) Stock Declines While Market Improves: Some Information for Investors
Express News | J&J - Currently Approved Intravenous Formulation of Rybrevant (Amivantamab-Vmjw) Is Not Impacted by Crl
Express News | J&J - FDA Issued Crl for Bla for Combination of Amivantamab & Recombinant Human Hyaluronidase for Subcutaneous Amivantamab
Dow's 111-Point Drop Led By Losses For UnitedHealth, Verizon Shares